去纤维钠（去纤苷）去哪买？

(Defitelio) is produced in Italy and is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD. However, China has not yet officially approved this life-saving drug, so helpless patients' families can only seek help online, looking for ways to purchase the drug. So, where can I buy defibrinated sodium (defibrotide)?

So far, defibrotide sodium (defibrotide) has been marketed in many countries and regions such as the European Union and the United States, and patients in these listed countries can buy the medicines they need. However, this drug has not yet been approved for marketing in China, so patients in need can only choose defibrinated sodium sold overseas.

It is understood that a box of 200mg defibrinated sodium sells for around $21,600. Due to exchange rate fluctuations, drug prices will change, so you need to consult Medical Companions for specific prices. At the same time, if patients need it, they can also contact Medical Companion Travel to obtain their drug purchase channels. In this way, patients can obtain the drugs they need more conveniently.

After purchasing defibrinated sodium, patients must follow the instructions or follow the doctor's advice: the recommended dosage of defibrinated sodium is 6.25 mg/kg, given every 6 hours as a 2-hour intravenous infusion. The minimum treatment time is 21 days. If the signs and symptoms of patients with hepatic veno-occlusive disease do not resolve after 21 days, the patient should continue treatment until the symptoms are resolved. 

The most common adverse reactions (incidence rate ≥10%) when using (Defitelio) are vomiting, hypotension, diarrhea, nausea and epistaxis. Although these adverse reactions are relatively mild and do not pose a serious threat to patients' health, patients still need to pay attention to avoid more serious adverse events.

Recommended hot articles: /newsDetail/78646.html